Delhi HC seeks response on Natco's patent challenge plea

The Delhi High Court is reviewing Natco Pharma's challenge to a breast cancer drug patent. Natco alleges Novartis and Astex secured two patents for the same invention. This action, Natco claims, unlawfully extends patent protection for the Ribociclib molecule. The court will first determine the petition's maintainability after legal arguments. The case has been scheduled for further hearing on September 16.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m8p3J7K
via IFTTT

Read More

Cipla, Rocket India announce Rs 300 crore expansion plans in Karnataka; Blackstone eyes data centres

Cipla and Rocket India will invest Rs 300 crore in Karnataka's manufacturing facilities. Blackstone is exploring investments in data centers and renewable energy infrastructure. Saint-Gobain plans to expand its manufacturing footprint within the state. Horizon is encouraged to consider industrial projects in tier two cities. These announcements occurred during Karnataka's investment roadshow in Mumbai.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W46dIZb
via IFTTT

Read More

IPA seeks to regularise 'legacy' drugs

The Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examples include sodium valproate and carbamazepine tablets. Regulatory gaps have persisted for over a decade. This situation requires urgent attention from drug authorities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vClqPwm
via IFTTT

Read More

Dr Reddy's Laboratories launches generic Sugammadex injection in the United States

Dr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effects given during surgical procedures. The company's hospital portfolio expands with this important medicine's availability. Sugammadex injection is a vertically integrated product manufactured through Dr Reddy's global network. This launch occurred on the first day of generic availability in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SiFyJOU
via IFTTT

Read More

India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says

India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncertainty and Middle East shipping disruptions hurt exports, Pharmaceuticals Export Promotion Council of India Chairman Namit Joshi told Reuters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/867Jmlf
via IFTTT

Read More

Private equity firm Creador in talks to buy into generic drug co Leeford Health

Private equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acquisition would value the generic drugmaker at ₹8,000-₹8,500 crore. Leeford Healthcare is a diversified pharmaceutical and wellness company. This deal marks the company's first ownership dilution to an external investor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kf5xhTv
via IFTTT

Read More

Two-wheeled road ambulance to run from October 1, 2027

The Centre has proposed introducing a regulatory framework for two-wheeled road ambulances, which will become operational from October 1, 2027, to improve emergency medical access in rural, remote and hilly areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKeP0ZV
via IFTTT

Read More

Losing weight fast on GLP-1 drugs? Your hair could be the next thing to go

Dermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen effluvium, stems from nutritional deficiencies and metabolic stress. Many patients start these medications without proper medical supervision, influenced by social media trends. Studies show a high prevalence of hair shedding, particularly among women and significant weight losers. Doctors advise medical supervision and balanced nutrition to manage this temporary condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSpeEKr
via IFTTT

Read More

India's Second Leapfrog: From sick-care to AI-native health infrastructure

Just as India bypassed copper landlines to become a global mobile data leader, it can now bypass the West's CPT-coded sick-care bureaucracy and build AI-powered, personalised healthspan infrastructure for the world.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VWaiTPn
via IFTTT

Read More

GLP-1 demand stirs up hunger for obesity care talent

Demand for nutrition professionals is rapidly increasing across India. Hospitals and digital health platforms are hiring more dietitians and educators. This trend supports patients using new GLP-1 obesity medications. Specialized obesity care teams are expanding to meet growing patient needs. Long-term monitoring and lifestyle support are crucial for sustained health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7SEy0he
via IFTTT

Read More

Jackson Labs' Baddi drug manufacturing licence restored after suspension

The unit's licence was cancelled in June after several women in Kota, Rajasthan, died allegedly due to spurious oxytocin injections supplied by the company's Punjab unit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/agUXoKF
via IFTTT

Read More

Sun Pharma recalls eye drops in India after contamination scare

"Withdrawal of Product - Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F & Nepalact E/D 5ML."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/I9GNHCo
via IFTTT

Read More

TPG, Permira emerge as frontrunners in Rs 11,000 crore Cloudnine sale

TPG Capital and Permira are leading contenders for a significant minority stake in Cloudnine. The deal is expected to value India's largest maternity and pediatric hospital chain at approximately ₹11,000 crore. Binding bids are anticipated by mid-August after due diligence is complete. This transaction will facilitate True North's full exit after over a decade of investment. Cloudnine posted ₹2,000 crore revenue and ₹300 crore Ebitda in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wR8BM2
via IFTTT

Read More

Lupin launches generic Sugammadex injection in US

Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Administration for its abbreviated new drug application. The company's injection is claimed to be bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade in adult and pediatric surgical patients. The launch occurred on Friday, as per a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BKHaYWf
via IFTTT

Read More

As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent Pharmaceuticals

Torrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman Mehta leads the firm with an ambitious future vision. He spearheaded a significant acquisition and focuses on weightloss drugs. Mehta emphasizes making the right strategic decisions for success.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aa2ZNnG
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis' India listed unit in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6yfHqpD
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis India in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xmdxj2f
via IFTTT

Read More

FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

The FSSAI has suspended Dior Pharmaceuticals' license due to serious violations. The nutraceutical factory operated with severely deficient good manufacturing practices. These deficiencies posed a significant risk to public health and safety. The company failed to ensure product safety, quality, and traceability. All operations must cease until compliance is fully established.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SpORKHG
via IFTTT

Read More

Gland Pharma gets USFDA nod for generic sugammadex injection

Gland Pharma secured USFDA approval for its sugammadex injection generic version. This drug reverses muscle relaxant effects used during surgical procedures. The approval covers two specific strengths of the single-dose vial product. This new generic is bioequivalent to Merck's BRIDION injection. The product had significant US sales in the past year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NQSndia
via IFTTT

Read More

Biocon gets Health Canada nod for Yesintek autoinjector pen

Biocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for psoriasis. The autoinjector is also indicated for psoriatic arthritis and Crohn's disease. This approval strengthens Biocon's immunology product portfolio in Canada. The company aims to increase patient access to affordable medicines globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npFjlZO
via IFTTT

Read More

BDR Pharmaceuticals eyes controlling stake in Acme Formulation

PAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder and managing director Viral Shah retained a significant minority stake after the transaction and continued as managing director and CEO. PAG owns about 62% of the company, while Shah holds around 31%, with the balance is owned by other investors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JmlhNyz
via IFTTT

Read More

Andhra Pradesh teams up with AstraZeneca for next-gen cancer care model

Andhra Pradesh signed an MoU with AstraZeneca for an integrated precision oncology ecosystem. This initiative will integrate artificial intelligence and advanced genomics for cancer care. The collaboration aims to transform patient journeys from screening to follow-up. AstraZeneca will deploy AI-powered solutions for early lung cancer detection. An Integrated Genomic Solutions Centre will expand access to advanced cancer diagnostics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/icoxMLN
via IFTTT

Read More

Alembic Pharma gets USFDA approval for generic chronic constipation treatment tablets

Alembic Pharmaceuticals announced USFDA approval for its generic prucalopride tablets. The company received final approval for strengths of one and two milligrams. These tablets are indicated for treating chronic idiopathic constipation in adults. The approved drug is therapeutically equivalent to Takeda's Motegrity tablets. This market segment has an estimated size of one hundred million dollars.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wv8WLxY
via IFTTT

Read More

Sakar Healthcare posts Rs 10-crore profit in Q1

Sakar Healthcare announced a substantial net profit increase for the first quarter of 2026-27. The company's revenue from operations also saw a significant rise during the same period. Its oncology business remains a key strategic focus for the pharmaceutical manufacturer. Sakar Healthcare executed numerous oncology product contracts and has many discussions ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZGICO6T
via IFTTT

Read More

Centre readies healthcare compliance overhaul to boost hospitals in tier-2, tier-3 cities

India plans major healthcare regulatory changes soon. These reforms aim to simplify licensing and reduce compliance burdens. The government will release a consultation paper within two months. This initiative seeks to encourage private investment in smaller cities. The goal is to improve healthcare access across the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CrMLy1Q
via IFTTT

Read More

PHC Mogla brings healthcare closer to Rajouri's remote villages

PHC Mogla now offers essential healthcare services locally. Residents previously traveled long distances for basic medical treatment. A portable X-ray machine aids emergency care for injured patients. Maternal healthcare has also seen significant local improvements. This facility has become a crucial lifeline for remote villagers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0d3FwBE
via IFTTT

Read More

US tariff proposal wake-up call for Indian pharma to diversify, innovate: Experts

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market reliance. There are warnings that ensuring patient access to affordable medications should remain paramount.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yst4R6k
via IFTTT

Read More

Sculpt, lift, glow: Face fitness is having a moment in India

Face fitness is emerging as a new category in India’s beauty and wellness market, blending facial massage, muscle stimulation and skincare into studio-led treatments. Premium brands and homegrown players are expanding as consumers seek non-invasive alternatives to aesthetic procedures, driven by growing interest in wellness, grooming and preventive beauty.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lzFpKvR
via IFTTT

Read More

Aster DM Quality Care to invest Rs 1,315 crore in Karnataka

Aster DM Quality Care will invest Rs 1,315 crore in Karnataka's healthcare infrastructure. This significant investment aims to strengthen the state's medical facilities and services. The company plans to develop new hospitals and expand existing ones in Bengaluru. These developments will enhance access to advanced tertiary and quaternary care. The commitment underscores Aster's long-term confidence in Karnataka's healthcare ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gX19DFN
via IFTTT

Read More

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company aims for significant revenue growth by 2030 through new drug launches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/deDbnmy
via IFTTT

Read More

FSSAI suspends Rehaan Healthcare licence over serious food safety violations

FSSAI has suspended Rehaan Healthcare’s licence after inspections revealed serious violations at its health supplements and nutraceutical manufacturing facility. The regulator found extremely unhygienic conditions, poor infrastructure, pest infestation, inadequate storage, and major food safety lapses, resulting in a very low compliance score of 12%. The company has been ordered to halt production until all deficiencies are rectified and verified by the competent authority, failing which legal action may follow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5PjhQJ
via IFTTT

Read More

Jackson Labs seeks restoration of its licence

The cancellation issued by the Punjab government followed reports that five women in Kota, Rajasthan, died after allegedly being administered an Oxytocin injection that upon testing found contained no active ingredient.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T9z30Rj
via IFTTT

Read More

India contributes one-third of global oral cancer burden; early detection key to survival, says oral cancer expert

India contends with a pressing oral cancer crisis, with thousands of new diagnoses and deaths emerging annually. The predominant factor behind this disease is the consumption of tobacco in diverse forms. Early detection via screening plays a critical role in managing and treating oral cancers successfully. It’s vital to monitor potentially malignant disorders closely and seek rapid medical assistance for ongoing oral health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8OHqfZa
via IFTTT

Read More

Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practical

US President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export significant generic medicines to the United States market. The proposed tariffs are set to begin in 2028, offering a two-year window. This lead time allows Indian firms to explore alternative export markets and adapt. American patients and insurers will likely face increased healthcare costs after tariffs are imposed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WvB3al9
via IFTTT

Read More

Dr Reddy’s aims to resume semaglutide supply by November after API fix

Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September. Financial results were impacted by a provision linked to the semaglutide active pharmaceutical ingredient. Despite disruptions, Dr Reddy's maintains its growth and profitability guidance for fiscal year 2027. The drugmaker anticipates supplying millions of semaglutide units this fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xl093uB
via IFTTT

Read More

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After this period, tariffs will escalate significantly, impacting export economics. Several Indian firms already have US manufacturing operations for flexibility. The next two years will shape how India serves its largest overseas pharmaceutical market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PsQ6hON
via IFTTT

Read More

Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the immediate impact on exports is likely to be limited, the proposed escalation to 100% and eventually 200% tariffs could significantly alter the economics of supplying generic medicines to the US if manufacturers do not establish a stronger local production footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYmzZXp
via IFTTT

Read More

ICMR licenses cancer, vaccine technologies to Emcure, Biological E

The Indian Council of Medical Research has licensed three new biomedical technologies. These innovations aim to advance cancer treatment and infectious disease protection. One drug candidate targets precancerous cervical cells, offering a safer treatment option. Two vaccine candidates will combat major bacterial gut infections. This initiative promotes government research into practical healthcare products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gzI0XQD
via IFTTT

Read More

Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn Saldanha

Glenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from its traditional generics-led model. The company is developing next-generation products targeting oncology and other complex diseases. Glenmark aims to become a global powerhouse in oncology within ten years. Artificial intelligence will significantly accelerate drug discovery and development processes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jktyj1a
via IFTTT

Read More

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms of seasonal allergic rhinitis effectively. RYALTRIS combines antihistamine and corticosteroid in one formulation. This marks a significant step in expanding access to the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yL6MSw9
via IFTTT

Read More

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

India's drug regulator has approved Takeda's Qdenga dengue vaccine, the first of its kind. This vaccine is expected to become available in India during the first half of 2027. Qdenga offers protection against all four dengue virus serotypes for individuals aged four to sixty. The vaccine demonstrated significant efficacy in late-stage trials, reducing cases and hospitalisations. Takeda is also partnering with Biological E to boost global manufacturing capacity for Qdenga.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uXcade9
via IFTTT

Read More

Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated steatohepatitis in adults. Poviztra contains innovator semaglutide manufactured in Europe by Novo Nordisk. The approval expands access to treatment for this progressive liver disease. This marks a significant milestone for patients with this serious condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/go3BxmL
via IFTTT

Read More

Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGA

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individuals aged four to sixty years old. QDENGA offers protection against all four dengue virus serotypes without prior testing. The vaccine has been approved in forty-three countries since its launch. India accounts for a significant portion of the global dengue burden.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eYgG18d
via IFTTT

Read More

Alcon to step up India investments; focus on innovation, training, says Senior Vice Prez Rajkumar Narayanan

Alcon is significantly increasing its investments in India's eye care market. The company sees India as a crucial emerging growth market for its future. Rising eye disorders among younger Indians are a key driver for Alcon's expansion. Alcon plans to enhance innovation and surgeon training programs across the nation. Future manufacturing in India is also being actively evaluated by the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Amds2LF
via IFTTT

Read More

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4 billion. Commercial launch depends on ongoing litigation, marking a regulatory milestone.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4tEAoYG
via IFTTT

Read More

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pCcdEbT
via IFTTT

Read More

Screens are straining young eyes, and Alcon sees India's opportunity

Alcon is increasing investments in India, recognizing its significant emerging market potential. The company focuses on innovation and surgeon training to address rising eye care needs. India's large population and growing myopia present substantial future growth opportunities. Alcon aims to enable advanced cataract care for millions by the year 2030. The global eye care leader is also evaluating future manufacturing possibilities within India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r3T1AC4
via IFTTT

Read More

Poly Medicure bets on new facilities, products to double international business: MD

The company's international business contributed ₹1,280.2 crore in FY26, accounting for nearly 68% of the company's total revenue of ₹1,875.3 crore. It expects the next phase of growth to be supported by two upcoming manufacturing facilities, a pipeline of more than 50 products, and a sharper focus on direct-market operations across key overseas geographies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VupHFhy
via IFTTT

Read More

Pharma exports to UK may rise up to 10% in FY27 as CETA takes effect

India's pharmaceutical exports to the UK are set to witness substantial growth thanks to the recently negotiated Comprehensive Economic and Trade Agreement. This groundbreaking agreement removes almost all tariffs on Indian drug products, enhancing the competitiveness of Indian generics and finished formulations. Preliminary data indicates promising trends in exports for this fiscal year, solidifying the UK's importance as a critical European market for India's pharmaceutical sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BSWdxhj
via IFTTT

Read More

India-UK FTA projected to boost Indian pharma exports by over 8% to $981 million in FY27: Pharmexcil

Indian pharmaceutical exports to the United Kingdom are projected to grow significantly. The India-UK Comprehensive Economic and Trade Agreement will eliminate tariffs on most products. This pact is expected to enhance the competitiveness of Indian generic medicines in the British market. The agreement also aims to secure supply chains and improve access to affordable medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sOz9NkP
via IFTTT

Read More

NITI Aayog roadmap targets USD 691 bn bioeconomy by 2035; Jitendra Singh says India ready to lead biotech revolution

India's bioeconomy can reach USD 691 billion by 2035, creating millions of high-value jobs. The nation aims to become a top global biotechnology power, driving future growth. A roadmap proposes six National BioMissions and a significant growth fund for development. Talent development, including engineering biology courses, is deemed critical for this ecosystem. This expansion will address national goals like health and food security.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jUBDlbs
via IFTTT

Read More

Kota kidney damage victims seek euthanasia or treatment in plea to President

Five women demand euthanasia after suffering kidney damage post C-section surgeries. They allege negligence and substandard drugs caused their critical health condition. Families face financial distress as husbands provide constant care for the ailing women. Repeated appeals to officials have yielded no resolution for their urgent medical needs. The petition seeks immediate kidney transplants and compensation or permission for dignified euthanasia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5GPctyg
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in Rs 1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bWKc1ym
via IFTTT

Read More

Jitendra Singh releases Rs 1,500 crore under third phase of Biomedical Research Career Programme

Union Minister Jitendra Singh released fifteen hundred crore rupees for the Biomedical Research Career Programme. This funding supports outstanding biomedical researchers and promotes collaborative research initiatives. The program, initiated in two thousand eight, has supported over five hundred researchers. It has also strengthened research across more than two hundred institutions nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JrUtK9b
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xiPgYI4
via IFTTT

Read More

Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetes

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement diet and exercise for adults. The company plans to launch the product soon in injectable pens. South Africa is the second market after India for this approval. This reflects Sun Pharma's commitment to improving access to generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S7kuYoN
via IFTTT

Read More

OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars

OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EtkJz94
via IFTTT

Read More

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta plaques in the brains of Alzheimer's patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oj2OFg0
via IFTTT

Read More

Warburg, Bain, CVC among PE firms in talks to buy into Agappe Diagnostics

Several global private equity firms are exploring a significant stake purchase in Agappe Diagnostics. This potential deal involves both existing investor sales and new capital infusion. The transaction is expected to value the Kochi-based in-vitro diagnostics firm at over three thousand crore rupees. Agappe Diagnostics develops and manufactures diagnostic reagents and equipment for global markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GAwaOnq
via IFTTT

Read More

Emcure buys remaining 12.05% in Gennova to take full control

Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be led by Samit Mehta for its next growth phase. The company will continue leveraging its biomanufacturing platforms for new products. Gennova's former CEO Sanjay Singh has divested its mRNA business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VYAtfO9
via IFTTT

Read More

First vaccine for Bundibugyo Ebola hits human trials in Oxford study

Oxford's Ebola vaccine candidate has entered Phase 1 clinical trials for safety evaluation. The ChAdOx1 BDBV vaccine uses a platform similar to the Covid-19 vaccine. Serum Institute of India manufactured approximately 620,000 doses for potential future use. This initiative builds on a strategic partnership with CEPI and the University of Oxford. Late-stage trials will follow if Phase 1 results prove successful.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ykevW63
via IFTTT

Read More

Schedule H1 explained: Why did India tighten its prescription rules for high-alcohol medicines?

Schedule H1 Explained: High-alcohol oral medicines now require a doctor's prescription under Schedule H1. This stricter classification mandates detailed sales records for pharmacies. The government aims to prevent misuse and diversion of these potent preparations. Previously exempt alcohol-based tonics face new licensing and prescription rules. Patients will need valid prescriptions for these medicines moving forward.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y318qeg
via IFTTT

Read More

Pharma body renews push for data protection

Leading pharmaceutical companies seek Regulatory Data Protection to boost research investments. Public health groups and local makers oppose this, fearing extended monopolies and delayed generics. The Organization of Pharmaceutical Producers of India argues it benefits indigenous drug makers too. China has already implemented similar clauses, seeing significant research deal growth. India's regulatory alignment with global practices could attract discovery research investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RGLQobI
via IFTTT

Read More

Antibiotic resistance emerging as major threat to surgical care: Experts

Antimicrobial resistance now challenges routine surgical procedures and increases infection risks. Surgeons warn that losing effective antibiotics undermines decades of progress in safe surgery. Hospitals are adopting stricter antibiotic stewardship and infection prevention measures. Multidrug-resistant organisms pose a significant challenge to treating post-operative infections effectively. Preserving antibiotic effectiveness is a shared responsibility for future generations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wU9h0H
via IFTTT

Read More

Maharashtra FDA bars sale of two Cadila drugs over branding concerns

Maharashtra FDA has seized Cadila Pharmaceuticals drug stock worth Rs 2.45 crore. The action was taken due to similar branding on different active ingredients. Officials barred sales of Aciloc 150 Plus and Aciloc 300 Plus medicines. This move aims to prevent medication errors and safeguard public health. Further investigation and legal action are currently underway.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JnbCdmg
via IFTTT

Read More

Medicines with over 12% alcohol can no longer be sold without prescription: Govt

In a new regulatory change, medications with alcohol content exceeding twelve percent will require a prescription from a doctor. This decision treats these products like standard prescription drugs, compelling manufacturers to obtain the necessary licenses. Furthermore, pharmacies are now tasked with rigorous record-keeping to mitigate potential abuse and ensure that genuine medical use is preserved under enhanced scrutiny.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KFcNM9Q
via IFTTT

Read More

Dr Reddy’s pauses weight loss drug on quality fears

Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the active pharmaceutical ingredient manufacturing scale-up. The company assures that already supplied market products remain safe for patient use. Torrent Pharmaceuticals and USV Ltd are recalling some semaglutide batches sourced from Dr Reddy's. Commercial supplies are expected to resume after the issue is resolved and validation is complete.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dwmf6Hl
via IFTTT

Read More

GA-Renova & CCA in race to buy American oncology: Siemens Healthineers looking to exit non-core business for Rs 1,500 crore

Two prominent players are in the running to purchase American Oncology Institute from Siemens Healthineers. One of the potential buyers is General Atlantic in collaboration with Renova Hospitals, while the other contender is Raj Mantena's Cancer Centers of America. Siemens Healthineers initially acquired this cancer network as part of a larger strategic agreement. The completion of the sale is anticipated by mid-August.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SNcbioP
via IFTTT

Read More

Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient concern. The firm is actively investigating to identify the source of the problem and is implementing corrective strategies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0z2tmvd
via IFTTT

Read More

Novo Nordisk readies once-a-week insulin shot for Indian market

Novo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment drastically cuts down the number of insulin injections from 365 annually to only 52. Awiqli could redefine the approach to diabetes management, offering promising cost savings compared to existing therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ChAb7oH
via IFTTT

Read More

Cultural sensitivity, communication key to strengthening India's medical tourism appeal: IIM experts

Experts highlight cultural sensitivity and communication's importance for international medical tourists. Effective expectation management and communication enhance patient experiences in Indian hospitals. India is a leading medical tourism destination due to advanced healthcare and affordable costs. Hospitals should invest in intercultural communication training for professionals. Bridging cultural gaps improves patient satisfaction and India's market competitiveness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OCSImb8
via IFTTT

Read More

Navi Mumbai Airport notified as port for import of drugs under Drugs Rules

Navi Mumbai Airport has been designated as a port for drug imports, a decision that boosts the pharmaceutical supply chain and simplifies trade activities. Following the amendment to Drugs Rules, 1945, the total number of notified ports has increased to 42. This initiative is aimed at facilitating efficient movement of pharmaceutical goods and enhancing regulatory oversight, showcasing the government's dedication to improving trade dynamics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AWFJEtN
via IFTTT

Read More

Regulator seeks views to curb similar sounding drug brands

The Central Drugs Standard Control Organisation in India is inviting public contributions concerning new regulations aimed at curbing the sale of various medications under similar brand names, which can mislead both patients and pharmacists about their contents. As part of this initiative, the drug regulator has released a notice for stakeholder observations, with a deadline for comments set for July 17 to ensure improved safety and trust among patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nTO3oJP
via IFTTT

Read More

India's wellness industry poised for growth amid focus on preventive healthcare, rising income: EBG Group chief

India's wellness market, valued at over $150 billion, is set for growth fueled by rising health consciousness and disposable incomes. EBG Group is launching Carlton Wellness India, an integrated ecosystem blending traditional Indian healing with modern hospitality. This platform will offer diverse wellness experiences, from city centers to retreats, emphasizing preventive care and holistic wellbeing for everyday life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WPFLkpU
via IFTTT

Read More

Gene therapy firm Immuneel ties up with Arogya Finance to offer Rs 25 lakh zero-cost EMI for cancer treatment

Immuneel Therapeutics collaborates with Arogya Finance to unveil a zero-cost EMI scheme for advanced cancer treatments, providing support of up to Rs 25 lakh. This effort is a segment of Immuneel's Saksham Patient Access Program, letting eligible patients benefit from interest-free installments for as long as 12 months, thereby reducing financial pressures and facilitating prompt access to essential therapies for those in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9GLTgKS
via IFTTT

Read More

Glenmark launches generic Olanzapine injection in US

Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States, offering a treatment for schizophrenia and bipolar disorder. This move by its US arm, Glenmark Pharmaceuticals Inc., introduces a bioequivalent alternative to Zyprexa intramuscular injection. The company aims to expand its injectable offerings and bolster its presence in the institutional market, targeting a segment with significant annual sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cZKjp6i
via IFTTT

Read More

Death in a vial: Five cases lay bare many uncomfortable truths about Indian healthcare

Five young mothers in Kota died after childbirth, with suspicion falling on oxytocin injections. Investigations revealed the vials contained only water, not the active ingredient. The manufacturer, Jackson Laboratories, has had stop-production orders earlier as well. This incident has put focus on critical failures in drug regulation and raises serious concerns about patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iaItPh9
via IFTTT

Read More

Adani Group to set up 2,000-bed hospital in New Town: Bengal CM

West Bengal Chief Minister Suvendu Adhikari announced that the Adani Group will establish a 2,000-bed hospital in New Town. A significant portion, 1,000 beds, will be dedicated to providing free treatment for the underprivileged. The remaining beds will be utilized for commercial operations. This initiative was revealed during an interaction with civil society members, highlighting the government's recent efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MkG8EVN
via IFTTT

Read More

OnCare launches cancer treatment centre in Bengaluru

Bengaluru now has a new cancer treatment centre launched by OnCare, aiming to bring accessible, affordable, and patient-friendly oncology services to the region. Following success in Delhi-NCR, the facility offers comprehensive care including chemotherapy, immunotherapy, and supportive services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4oBSebW
via IFTTT

Read More

Fortis Healthcare inks pact with Dion Group for 300-bed hospital in Cuttack

Fortis Healthcare is set to manage and operate a new 300-bed multi-specialty hospital in Cuttack, Odisha, a project valued at Rs 600 crore. Developed by Dion Group, the facility aims to significantly enhance access to advanced tertiary care for residents of Cuttack, Bhubaneswar, and surrounding areas. This collaboration merges Fortis's extensive healthcare expertise with Dion's infrastructure development vision, promising quality medical services closer to home.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mTuJNxy
via IFTTT

Read More

Sun Pharma secures relief in 'Pantocid' trademark dispute

Delhi High Court has halted Ahmedabad-based Finecure Pharmaceuticals from producing and selling drugs with names similar to Sun Pharma's 'Pantocid'. The court permitted Finecure to sell existing stock of 'Pantopacid' within four months, provided an affidavit detailing the inventory is filed. This decision overturns a previous ruling that had refused to grant an injunction against Finecure, highlighting significant sales disparities between the two companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j2dpVz7
via IFTTT

Read More

Syngene International MD & CEO Peter Bains resigns

Bains has resigned from the position of MD & CEO with effect from the close of business hours on June 30, Syngene International said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YdApZaN
via IFTTT

Read More

Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test

Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made possible through an agreement with Guardant Health. This innovative blood test can identify signals for multiple cancer types in individuals aged 45 and above. The collaboration aims to enhance early cancer detection and improve patient outcomes across the nation, making advanced screening more accessible.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7sBNd9h
via IFTTT

Read More

New rules simplify drug launches, reduce manufacturer liability for overcharging

New rules now allow drug manufacturers to launch similar medicines without prior price approval, streamlining market entry. Companies can seek varied prices for drug variants based on packaging and dosage, fostering flexibility. Overcharging liability is now limited to specific distributors if manufacturers prove compliance, easing burdens for many firms. Stricter record-keeping for seven years is also mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ciaZRXt
via IFTTT

Read More

Shantha Biologics to make injectable drug cartridges for Novo Nordisk

Shantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable medicines at its Hyderabad facility. This partnership highlights India's growing role in advanced pharmaceutical manufacturing, particularly for high-demand diabetes and obesity therapies. Shantha's FDA-approved, automated fill-finish lines will produce these critical components, underscoring the company's expanding capabilities in contract manufacturing for biologics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eqmNj5D
via IFTTT

Read More

Generics must not be imperiled over data protection: Satish Reddy, Chairman, Dr Reddy's Laboratories

Dr Reddy's chairman, Satish Reddy, has raised concerns about compromising India's competitive edge in generics for foreign investments. He stresses the importance of aligning capital with developmental needs and enhancing collaboration between academia and industry. Advocating for a national mission akin to China's, he highlights the necessity of structured government procurement to stimulate drug innovation and underscores AI's transformative role in drug discovery, contingent on adaptive regulatory systems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zy56Brh
via IFTTT

Read More

Telangana bets big on drug discovery hub

Telangana is gearing up to elevate Hyderabad's pharmaceutical standing beyond manufacturing. The state is fostering an integrated ecosystem for drug discovery and development, bringing together industry, research, startups, and investors. This strategic move aims to position Telangana as a hub for next-generation therapies, leveraging its existing strength as a global vaccine production leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O9uben6
via IFTTT

Read More

Mankind Pharma partners Denovo Sciences for AI-led drug discovery

Mankind Pharma has partnered with Denovo Sciences to accelerate drug discovery using artificial intelligence. This collaboration aims to significantly cut down early research timelines, enhance the quality of potential drug candidates, and ensure only the most promising ones advance. By combining Mankind Pharma's R&D prowess with Denovo's AI platform, the companies expect to bring effective and accessible treatments to patients faster, marking a significant step in innovation-driven research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GtiF5H8
via IFTTT

Read More

mRNA vaccines protect against severe infectious diseases, review confirms

Billions of mRNA vaccine doses administered globally confirm their safety and effectiveness against infectious diseases, including severe COVID-19, across all age groups and health conditions. Researchers emphasize that serious side effects are rare, with benefits far outweighing risks. This technology, now proven, holds immense promise for future vaccines and personalized treatments, though equitable global access remains crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZiMdsJ0
via IFTTT

Read More

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma has joined forces with Denovo Sciences to revolutionize drug discovery using artificial intelligence. This strategic partnership aims to significantly shorten development timelines, improve the quality of potential drug candidates, and identify the most promising options. By integrating AI with human expertise, the companies are set to accelerate the delivery of effective and accessible new medicines to patients, marking a significant step forward in pharmaceutical innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oHUbqxj
via IFTTT

Read More

Telangana plans drug discovery push to move Hyderabad up pharma value chain

Telangana is charting a new course to elevate Hyderabad into a global drug discovery hub. The state is fostering an integrated ecosystem by creating shared infrastructure and funding for startups and researchers. This ambitious plan aims to accelerate the development of next-generation therapies, including cell and gene therapies, by leveraging existing strengths and forging new partnerships, positioning Hyderabad for significant advancements in pharmaceutical innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sxoj2Tm
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel

Alembic Pharmaceuticals has secured final USFDA approval for its generic Dapsone gel, a topical treatment for acne vulgaris. This approval, for the 5% strength, means the company can now market its version, which is therapeutically equivalent to Almirall's Aczone Gel. This development marks a significant step for Alembic in the US market, offering a new option for acne sufferers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nMls3jE
via IFTTT

Read More

India’s nutraceutical market set to nearly double to $57 billion by 2030 on preventive health boom

India's health-conscious population is fueling a boom in the nutraceutical market, projected to nearly double to $55-57 billion by 2030. This shift towards preventive care, supported by e-commerce and government initiatives, sees the sector growing at an impressive 10.5% CAGR. While regulatory efforts are strengthening, challenges like consumer awareness and scientific validation persist, yet the industry is poised for significant expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Na4JrkL
via IFTTT

Read More

Health ministry proposes faster approvals for medical device manufacturing licences

The Union health ministry is proposing to significantly cut down the time taken to issue manufacturing licenses for medical devices. Aimed at boosting ease of doing business and ensuring quicker access to quality products, the amendments will reduce timelines for low to high-risk devices. For instance, Class B devices will see a reduction from 140 to 115 days, and high-risk Class C and D devices from 105 to 90 days.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O2VZyaD
via IFTTT

Read More

Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore

Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth by infusing Rs 50 crore for future expansion. Strides will retain a 19.95% stake, while the investors will hold 65.05%. The transaction values Pivot Path at Rs 230 crore post-money.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Th4cZFf
via IFTTT

Read More

Shelf-life norms for imported drugs may be relaxed to reduce wastage

India is set to revise rules for imported medicines, proposing a 12-month minimum residual shelf life instead of the current 60% rule. This aims to ease business and reduce wastage, particularly for drugs with longer expiry dates. However, biological and radiopharmaceutical products will retain the stricter 60% requirement due to public health concerns. Other quality and safety regulations remain unchanged.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wThKdeR
via IFTTT

Read More

Centre set to tighten oversight of pharma packaging materials

India is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This move follows seizures of fake weight-loss drugs and vaccines, revealing that genuine packaging materials were being diverted and misused abroad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jsBbCfL
via IFTTT

Read More

India's GLP-1 boom slows amid price war, weak retention

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-expected prescriptions and patient retention. Unexpected price cuts from the innovator, coupled with the high cost of generics for Indian consumers, are impacting adoption. This has led to a wait-and-watch approach for upcoming launches, with a potential revival anticipated later in the fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5kmvBXf
via IFTTT

Read More

Eli Lilly launches cancer drug Tanstrive in India

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced or metastatic solid tumours with a rearranged during transfection (RET) gene, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IZDaN69
via IFTTT

Read More

NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chain

Niti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think tank urges a shift towards high-value segments, emphasizing enhanced industry-academia collaboration for patent commercialization and startup incubation. While India is the 'pharmacy of the world,' it needs to move up the value chain by focusing on deeptech innovation to become a capital for pharma innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Blf4C3J
via IFTTT

Read More

India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI Aayog

India's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearly 65% of APIs and intermediates sourced from there. NITI Aayog's report highlights supply chain vulnerabilities and calls for moving up the value chain by fostering innovation and industry-academia collaboration. This strategic shift aims to boost high-value product development and capture a larger global market share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pPlx4t3
via IFTTT

Read More

Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman role

Healthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna, instrumental in Healthium's growth and acquisitions since 2018, will aid in successor selection. Despite record revenue, the medical devices firm saw profits decline recently, facing market competition and a slowdown in the Indian surgical products sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y0Fua5X
via IFTTT

Read More

Stress, poor sleep and processed food are driving heart attacks in young Indians: Ramakanta Panda

Young Indian professionals, particularly in IT and finance, are facing a heart disease crisis due to unhealthy lifestyles. Leading cardiac surgeon Dr. Ramakanta Panda highlights chronic stress, poor sleep, processed foods, and sedentary habits as major culprits behind a surge in heart attacks among those in their 30s and 40s.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fy2aELA
via IFTTT

Read More

Central Drugs Laboratories find 46 drug samples not of standard quality for May

Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratories were found to be of substandard quality. Additionally, one spurious drug, manufactured by an unauthorized entity using another company's brand, was identified in Assam and is under investigation. These findings highlight ongoing efforts to ensure drug safety and remove substandard products from circulation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F2gpiGV
via IFTTT

Read More

Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately boost earnings per share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qi42rVf
via IFTTT

Read More

Jyothy Labs to expand Exo into broader dishwash franchise after Henkel brands exit portfolio

Jyothy Labs is strategically expanding its Exo dishwash brand into a comprehensive franchise following Henkel's exit from Pril and Fa licensing in India. The company remains cautiously optimistic about FY27 growth, focusing on premium products, innovation, and wider distribution despite inflationary pressures. New Exo variants are showing promising consumer response, aiming to boost sales and market share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NH5MPcp
via IFTTT

Read More

Scanning cancer, up close & personal: A revolution is underway in cancer diagnosis

A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Since the NGS test can be beyond the reach of many, a unique collaboration called LuNGS Alliance is making it free for lung cancer patients in India, offering a glimpse of how medical breakthroughs can be made accessible and affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tjgNuyO
via IFTTT

Read More

Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to conclude by July 2026, is a significant step for Sun Pharma's expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x6BPKQN
via IFTTT

Read More

Yoga may boost cognition, reduce depression, aid gut health in early Alzheimer's: AIIMS study

A 12-week yoga program has shown promising results for individuals with mild Alzheimer's disease. Researchers at AIIMS, Delhi, observed significant improvements in cognitive function and mood, alongside a healthier gut microbiome. The study suggests yoga may help restore beneficial gut bacteria, potentially influencing the gut-brain axis and offering a valuable complementary therapy for early-stage Alzheimer's and mild cognitive impairment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xbKZrwE
via IFTTT

Read More

Plan in the works to let hospitals import med equipment directly

India's drug regulator is proposing to allow hospitals to directly import advanced medical equipment like MRI and CT scanners, bypassing current import licenses. This move aims to speed up access to cutting-edge technology. However, the domestic medical device industry expresses concern, citing safety risks and the specialized expertise of licensed importers in handling high-risk equipment and ensuring quality.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iPEWgbe
via IFTTT

Read More

Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 cr

Global investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a 3 percent stake in Anthem Biosciences. The deal, valued at Rs 1,275 crore, saw promoter Aruna Ganesh exit the company. This significant transaction reshapes the promoter's holding in the integrated Contract Research, Development and Manufacturing Organisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/67R3r9I
via IFTTT

Read More

Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soon

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federal Trade Commission for its takeover of Lannett Company. This regulatory approval removes the final hurdle. The acquisition is expected to close by the end of June.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XzE6rDb
via IFTTT

Read More

HPV vaccination drive reaches 50 lakh girls in three months

India's free Human Papillomavirus vaccination drive is making significant progress. Nearly 50 lakh doses of the cervical cancer vaccine have been administered to 14-year-old girls. This initiative covers almost half of the 1.15 crore target population nationwide. Madhya Pradesh and Gujarat have already achieved 100% of their targets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/85l3uED
via IFTTT

Read More

US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisition

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a condition for Aurobindo Pharma to finalize its acquisition of Lannett Company Inc., ensuring no anti-competitive issues arise from the deal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u3jUDq4
via IFTTT

Read More

KKR eyes at least $1 billion stake in Medicover's India hospital arm, source says

Global investment firm KKR is in advanced discussions to acquire a significant stake in Medicover's Indian hospital operations. The deal is valued at over one billion dollars. Medicover, a Swedish healthcare group, confirmed these talks. This potential acquisition marks a substantial expansion for KKR in India's growing healthcare sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sc8UvWY
via IFTTT

Read More

API prices fall as West Asia tensions ease, boosting Indian pharma sector

Prices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West Asia, which has brought stability to supply chains. Indian pharmaceutical manufacturers are breathing a sigh of relief as they manage to offset rising input expenses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PFqER2
via IFTTT

Read More

Public-private projects key to expand access to Kidney care: NephroPlus

NephroPlus, India's leading provider of dialysis services, is on a mission to reshape the future of kidney health with an innovative tech-based platform aimed at preventing chronic kidney disease. As it scales up its network of dialysis centers both domestically and in global markets, this forward-thinking initiative seeks to combat the advancement of kidney ailments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wwvfs57
via IFTTT

Read More

Government prescribes end to over-the-counter sale of cough syrups

Even in small villages with a population of less than 1,000, where certain remedies including cough syrups were allowed to be sold without retail sale licences so far, now only duly licensed pharmacies can dispense cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1URFfBh
via IFTTT

Read More

Cloudnine's 25% stake sale attracts top global PE firms

Leading global private equity firms are in the running to acquire a substantial minority stake in Cloudnine, India's premier maternity and paediatric hospital chain. The deal is expected to value the company at approximately $1.2 billion. This strategic move will see existing investor True North exit, while other shareholders are likely to retain their positions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hou2fNW
via IFTTT

Read More

Zydus Lifesciences completes acquisition of Assertio

The company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding shares of common stock of Assertio Holdings Inc, Zydus Lifesciences said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HWTdaGt
via IFTTT

Read More

Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalizing on growing demand as major pharmaceutical companies shift focus to newer weight-loss drugs. Currently the third-largest global insulin provider, Biocon is significantly expanding production. This strategic move addresses a critical gap in the market, particularly in emerging economies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7cvhk2i
via IFTTT

Read More

Your shampoo may be cleaning your hair, but is it treating your scalp?

Most shampoos do a decent job of cleaning the hair shaft. But if you keep dealing with flakes, an itchy scalp, or that persistent oily feeling, the problem likely isn't your hair. It's what's happening underneath.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gGRMwAE
via IFTTT

Read More

Apollo Hospitals taps Shobana Kamineni to chair soon-to-be listed Healthtech unit

Apollo Hospitals is appointing Shobana Kamineni as executive chairperson of its upcoming medical equipment business, Apollo Healthtech. This move is part of a larger restructuring plan to unlock business value. Apollo Healthtech is expected to be listed separately. The company aims for significant revenue by listing. This signals a focus on growth and governance for the new entity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Rbf8iQ
via IFTTT

Read More

Novartis India launches Pluvicto for prostate cancer treatment

Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer cells, offering a new treatment approach for metastatic prostate cancer. The therapy will be available through select hospitals and nuclear medicine centers across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f1EnHrB
via IFTTT

Read More

India known as nation with world's largest healthcare programme: PM Modi

Prime Minister Narendra Modi said India has made healthcare more affordable and accessible over the past 12 years through initiatives such as Ayushman Bharat and the PM Bharatiya Jan Aushadhi Pariyojana. He highlighted lower-cost medicines and medical devices, expanded medical education, and progress in tackling diseases like tuberculosis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/b0K2LuN
via IFTTT

Read More

Maharashtra FDA bars hospitals from forcing patients to buy medicines in-house

Maharashtra's Food and Drug Administration has issued a significant directive. Hospitals and medical practitioners must now allow patients to purchase medicines from any licensed pharmacy. Patients will receive their prescriptions directly. This move aims to prevent unfair trade practices and protect patient consumer rights.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/htfYjdp
via IFTTT

Read More

Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriers

A new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While offering potential benefits, experts highlight concerns about its high cost and the need for early diagnosis. The drug's real-world impact in India remains a subject of discussion among neurologists and the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mp3YCOg
via IFTTT

Read More

India raises price cap on cancer drugs to tackle shortage

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused by a sharp rise in platinum costs. The National Pharmaceutical Pricing Authority (NPPA) approved the one-time hike in public interest after supply disruptions affected hospitals across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fkU3Y9y
via IFTTT

Read More

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected to reach over 100 billion dollars by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qb8KzFm
via IFTTT

Read More

Regulators tighten GMP oversight of pharma plants

Several states have constituted dedicated multi-member teams to ensure no facility slips through the cracks before a GMP Certificate is issued, people in the know told ET. The inspections will now be applicable to all manufacturing units without exception including MSMEs, which had previously been granted a relaxation period that lapsed in January.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nCWQ6U1
via IFTTT

Read More

India needs to remain attractive for innovation-led investment: Judith Love, Novartis

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GP6dNjY
via IFTTT

Read More

US drug regulator issues import alert for drugs made at a Dabur India plant

The US Food and Drug Administration has placed Dabur India's factory on an import alert. This action follows an inspection that revealed significant issues with data integrity and factory maintenance. Critical manufacturing records were reportedly falsified. Live birds and droppings were also found in a raw material warehouse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pa87rF2
via IFTTT

Read More

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wg9noPJ
via IFTTT

Read More

Government may lift price cap on cancer drugs making them costlier by up to 50%

India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy agents, faced shortages due to rising raw material costs. The government may allow significant price increases to boost production. This move aims to prevent treatment disruptions for thousands of patients across the nation. Revised prices are expected soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TVo6ZdO
via IFTTT

Read More

India's healthcare transformed in 12 years under PM Modi: Report

India's healthcare sector has seen a major transformation over the last 12 years. Health insurance coverage has expanded significantly. Maternal and child healthcare has improved. Medical infrastructure has seen a substantial increase. The government has focused on making healthcare accessible and affordable for all citizens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JnAVjwk
via IFTTT

Read More

Hetero partners with Richter to develop, market Semaglutide injection globally

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to expand global access to diabetes therapies. Regulatory filings are underway, with EU and US submissions planned for 2027. The partnership leverages Hetero's market presence and Richter's European network.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xtu7rKd
via IFTTT

Read More

Insider trading: Supreme Court upholds SAT clearance to Biocon MD

The Supreme Court has backed a tribunal's decision, clearing Biocon's managing director, Shreehas P Tambe, of insider trading allegations from 2017. The Securities and Exchange Board of India's appeal was rejected. Tambe was accused of trading Biocon shares while possessing unpublished price-sensitive information.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z6uFayf
via IFTTT

Read More

SBI in $1 billion funding for Sun Pharma’s US deal

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tFWdJlE
via IFTTT

Read More

Indian cancer patients battle shortage of key drugs as platinum costs surge

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues are causing shortages. This forces patients to search extensively for medication. Some drugmakers have reduced production. The situation puts immense pressure on the healthcare system and patients seeking treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32DvEAG
via IFTTT

Read More

India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician training and patient education are now crucial for future market expansion. Meanwhile, tirzepatide shows a recovery, maintaining its market position. Competition remains intense with numerous semaglutide brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9B16sJw
via IFTTT

Read More

India willing to open its market to high-quality, innovative pharma products, says commerce minister

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug exports. The Indian pharma market is set to double in five years. Global companies are invited to invest in India's vast market and skilled workforce. India is a major supplier of generic medicines and vaccines worldwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yUNzlbi
via IFTTT

Read More

Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supply

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbekistan a key hub for making and supplying medicines in the region. Simplified rules and tax benefits will encourage more investment. This move will boost local healthcare and strengthen trade ties between the two nations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzZ18xB
via IFTTT

Read More

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iIhEzGt
via IFTTT

Read More

Hospital expansion cycle to keep margins rangebound, but 18 per cent revenue growth trend likely to sustain: Kotak Securities

Indian hospitals are set for strong revenue growth. Brokerage firm Kotak Securities predicts double-digit gains. EBITDA margins are expected to remain stable. This outlook comes despite significant bed expansion. Hospital volumes and diagnostics are showing positive trends. The March quarter performance was robust, with sales and EBITDA growth reported. This indicates a healthy sector outlook for the coming period.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JCirLdg
via IFTTT

Read More

Regulator, cos discuss price hike for some cancer drugs

India's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin and cisplatin, are crucial for treating various cancers. The National Pharmaceutical Pricing Authority met with drug makers and hospital representatives to discuss the issue. Rising raw material costs have put pressure on production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ebQqRAr
via IFTTT

Read More

Manipal Health takes Bengaluru hospital building on long-term lease

Manipal Health Enterprises has leased a 245,000-sq ft multi-speciality hospital in Bengaluru's Yelahanka for nearly 30 years, with an estimated total rental outgo of ₹816.1 crore. The lease agreement includes a starting monthly rent of ₹1.27 crore and a 10% rent escalation in the sixth year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PG2n5xB
via IFTTT

Read More

PE wars to billion-dollar IPO dreams, hospital sector is fighting fit

Major private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition highlights strong investor confidence in India's healthcare sector. The industry is entering a new growth phase driven by increasing demand, a shortage of hospital beds, and a rise in specialized medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S3xQGYv
via IFTTT

Read More

Warburg, KKR, TPG among PE giants vying for 25% stake in Cloudnine

Global private equity giants, including Warburg Pincus and KKR, are vying for a 25% stake in India's largest maternity and pediatric hospital chain, Cloudnine. The deal is expected to value the company at approximately $1 billion, with existing investor True North exiting completely. Cloudnine reported revenues of ₹2,000 crore and EBITDA of ₹300 crore in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KIsAC3d
via IFTTT

Read More

Pharma exports to US seen muted this year

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are impacting shipments. US buyers are managing inventories more closely. A push for local manufacturing in the US also poses a challenge. This situation is creating caution among buyers for large forward orders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F3B7nNP
via IFTTT

Read More

Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facility

Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines for global markets. US pharma giant MSD is the first major client. The plant signifies Aurobindo's expansion into the growing biologics and contract manufacturing sector. It is set to create over 1,500 jobs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EQ7zZbD
via IFTTT

Read More

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IhibuV6
via IFTTT

Read More

Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordable for diabetes and obesity management. The company is the first in India to offer this convenient format. This move intensifies competition in the growing Indian drug market. Alkem aims to expand access to quality medicines for better patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZTqrRtK
via IFTTT

Read More

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access for affected nations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZVmTMeO
via IFTTT

Read More

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJinu2r
via IFTTT

Read More

GVK-backed Oval Fertility launched in Hyderabad, eyes share in India's growing IVF market

GVK family-backed Oval Fertility has launched its first premium IVF center in Hyderabad, leveraging advanced embryo monitoring technology. Co-founded by US fertility specialist Dr. Brian Levine and Veena Reddy, the venture aims to redefine fertility care with a blend of science, technology, and personalized patient experience. The clinic, priced at Rs 4.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTjstYo
via IFTTT

Read More

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

Wockhardt’s newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cAJZxhe
via IFTTT

Read More

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S8Y03QR
via IFTTT

Read More

Wockhardt secures US FDA approval for antibiotic Zaynich

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mrkbf30
via IFTTT

Read More

Molecule glue drugs shake up cancer care, draw big money

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l5uhT37
via IFTTT

Read More

Lincoln Pharmaceuticals posts Rs 11.63 crore profit for Q4

Lincoln Pharmaceuticals announced a slight profit rise for the fourth quarter ending March 31, 2026. Full fiscal year 2025-26 saw over 6 percent growth in consolidated net profit. Revenue from operations also increased year-on-year. The company's board recommended an 18 percent dividend. Lincoln Pharmaceuticals targets Rs 1,000 crore revenue in three years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/76Rj9yd
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6aAjqyO
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Goup CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3WLvRrg
via IFTTT

Read More

Zydus Therapeutics' saroglitazar drug granted priority review by US FDA

Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver disease. The company plans to launch saroglitazar in the US in the fourth quarter of fiscal year 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gNGJ9PZ
via IFTTT

Read More

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with chronic hepatitis B.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3KpX2D
via IFTTT

Read More

Wockhardt gets CDSCO nod for Zaynich antibiotic

Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections in adults. The approval follows successful clinical trials. Zaynich shows potential against drug-resistant bacteria. This marks a significant step in combating challenging infections.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JLseqSv
via IFTTT

Read More

India's out-of-pocket healthcare spending drops significantly, govt data shows

Indian families now pay less for healthcare. Out-of-pocket spending fell from 64.2% to 43.4% in ten years. This is due to the government spending more on public health. Government health expenditure as a share of GDP has also increased. Per capita spending on health has grown significantly. This shows a stronger health financing safety net for citizens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5kYMDTZ
via IFTTT

Read More

Gene therapy for cholesterol: Initial test results cheer

A new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in bad cholesterol. This one-time infusion could transform heart disease management. Larger trials are planned, with a Phase II trial starting soon. This approach may eventually benefit broader populations at high cardiovascular risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C6LDpzy
via IFTTT

Read More

Skymap Pharma to buy state-run Indian Medicines Pharma for Rs 121 crore

The inter-ministerial committee has officially sanctioned the acquisition of the Indian Medicines Pharmaceutical Corporation by Skymap Pharmaceuticals for a whopping ₹121 crore, securing a 100% ownership stake. This pivotal transaction marks the first strategic sell-off of a public sector entity in FY25, with the award letter now in circulation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZGuVTd5
via IFTTT

Read More

Government okays Skymap Pharmaceuticals' Rs 121-cr bid to buy IMPCL

The government has approved the sale of Indian Medicines Pharmaceutical Corporation Ltd. Skymap Pharmaceuticals Pvt Ltd will acquire the company for over Rs 121 crore. This strategic sale involves 100 percent stake and management control. IMPCL manufactures Ayurvedic and Unani medicines. The approval followed a competitive bidding process. The transaction is now being finalized.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DhAR0gZ
via IFTTT

Read More

Health services, medical education expansion to be driven by modern tech: Yogi Adityanath

Uttar Pradesh Chief Minister Yogi Adityanath reviewed health and medical education. He stressed improving treatment quality and expanding services. Medical colleges and nursing institutions will be strengthened with modern technology. Ayushman Yojana support for the poor was highlighted. Efforts are underway to enhance emergency services and control communicable diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zD0yKUT
via IFTTT

Read More

India medical tourism market feels the weight of Iran war

India's medical tourism sector faces challenges as West Asian tensions continue. Overseas patient numbers remain lower than before the conflict intensified. Hospital chains report a gradual increase in inquiries and arrivals, but traffic has not fully recovered. Prolonged geopolitical uncertainty could also raise operating costs through inflation and currency fluctuations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fNZH7yg
via IFTTT

Read More

Park Medi World to acquire Medicity Hospital in Rudrapur, enter Uttarakhand

Hospital chain Park Medi World Limited is acquiring The Medicity Hospital in Rudrapur. The deal is valued at Rs 177 crore and is an all-cash transaction. This acquisition marks Park Group's entry into Uttarakhand. The Medicity Hospital is a multi-super speciality facility with 330 beds. This move aligns with the company's growth strategy to expand its network in underserved markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HeNUzh6
via IFTTT

Read More

Sakar Healthcare partners with Zydus Lifesciences for GCC Markets

Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QytHJAx
via IFTTT

Read More

Kerala’s healthcare gold rush: How private equity is reshaping hospitals and raising fears over costs

Private equity funds are pouring hundreds of millions of dollars into Kerala’s healthcare sector, reshaping a system long dominated by independent doctors and family-run hospitals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/62xW7PU
via IFTTT

Read More

Venus Remedies gets Saudi FDA approval for speciality oncology therapy

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TFUKJvM
via IFTTT

Read More

Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AWZO8sX
via IFTTT

Read More

Fortis liability case: Delhi HC says blame can't be shifted to third party

Amid ongoing legal disputes, the Delhi High Court is probing Fortis Healthcare's oversight concerning the sale of shares belonging to the Singh brothers, former promoters of the company. The court's remarks suggest that Fortis had a responsibility to inhibit such transactions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r02xIH5
via IFTTT

Read More

Invisalign maker Align Technology to invest Rs 1,800 crore in Hyderabad plant

US firm Align Technology will invest Rs 1,800 crore in Hyderabad for its first Indian manufacturing plant. This facility will be the company's fourth globally. It is expected to create over 300 jobs. The investment will boost Align Technology's existing operations in the city. The new plant will support its worldwide production of clear aligners.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BphLCdz
via IFTTT

Read More

Pregabalin moved to Schedule H1 as centre cracks down on drug misuse

Pregabalin, a nerve pain medication, now faces stricter controls. The Union health ministry has moved it to Schedule H1. This change aims to curb its misuse, especially among youth. Previously available over-the-counter, it now requires strict prescriptions. Pharmacies must maintain records and display prominent warnings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Si5YHum
via IFTTT

Read More

ICMR replaces old system with single window approval for medical studies

The Indian Council of Medical Research has introduced a unified ethics approval process for multicentre medical studies, replacing the previous fragmented, site-by-site system. This significant reform aims to expedite research timelines, reduce costs, and expand participation to rural and vulnerable populations, fostering more representative and robust health policy evidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnMQj3G
via IFTTT

Read More

Eli Lilly’s obesity drug shows up to 30% weight loss in trial

Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple hormone receptors. The drug also improved heart health markers. Experts believe retatrutide could be a game-changer for treating obesity and improving patient health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FJEq4Sa
via IFTTT

Read More

No cosmetic job with jabs, warns drug regulator CDSCO

The notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the Cosmetics Rules, 2020.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QKycW0G
via IFTTT

Read More

India plans national registry to track implantable medical devices and patients

India is set to launch a national registry for implantable medical devices. This initiative aims to track all devices and patients, ensuring only certified products are used. The registry will help curb overuse and fix accountability. It will also aid in identifying patients during recalls and tracking real-world safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hDYFcAn
via IFTTT

Read More

Chemists’ strike: CDSCO moves to prevent shortages

The CDSCO has advised state drug controllers to prevent drug scarcity during the AIOCD's proposed e-pharmacy strike on May 20. Measures include ensuring pharmacies remain open, coordinating with police, and negotiating to keep some shops operational to avoid medicine deserts. The government emphasizes uninterrupted public access to medicines as a top priority.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uMGf1Jj
via IFTTT

Read More

NCLAT allows Lyka Labs appeal; asks Modi Lifecare to pay Rs 63 lakh or face insolvency proceedings

The NCLAT has ruled in favor of Lyka Labs. It overturned a previous NCLT decision. Modi Lifecare Industries must now pay Rs 63 lakh within 30 days. Failure to pay will lead to insolvency proceedings against the company. The tribunal found that Modi Lifecare acknowledged its debt. This ruling stems from unpaid royalties under a technical guidance agreement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xt5aeV0
via IFTTT

Read More

Hearzap to acquire Amplifon India, expand network to 420 hearing care centres

Hearzap is acquiring Amplifon India in a deal that will significantly expand the company's presence across the country. The combined entity will operate approximately 420 hearing care centers. With this move, Hearzap is seeking to strengthen position in the organised hearing care market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XzVcGMp
via IFTTT

Read More

Rising input costs, export slump take a toll on drug companies' health

India's drug makers are facing a double blow. A weaker rupee makes imported raw materials more expensive. Global economic worries are also slowing down demand for Indian medicines abroad. This is squeezing profits for manufacturers. Companies are trying to focus on more profitable products. The situation presents a tough operating environment for the industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UQdLPIH
via IFTTT

Read More

AbbVie loses patent plea for Hep C drug

The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to affordable treatment for millions. The patent office refused the application after AbbVie failed to contest oppositions and chose to abandon it. This refusal prevents AbbVie from extending its patent monopoly by five years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NztJA5p
via IFTTT

Read More

Pharmacy associations to skip strike, major medicine disruption unlikely

A planned nationwide pharmacy strike on May 20 is unlikely to occur. Many retail pharmacy associations have withdrawn support. This follows assurances from the Central Drugs Standard Control Organisation that concerns about e-pharmacies are under review. Public interest and patient welfare are cited as reasons for declining the strike. Medicine availability is expected to remain uninterrupted.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pHjOo03
via IFTTT

Read More

Athena opens northeast India’s largest integrated psychiatric hospital in Guwahati

Athena Behavioral Health opens Northeast India's largest private psychiatric hospital in Guwahati. This marks their fifth hospital nationwide. The facility offers integrated treatment for mental health and substance use disorders. It aims to address the region's growing needs and shortage of structured care. The launch signifies a crucial step in making quality mental healthcare accessible in underserved areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wKiVf3e
via IFTTT

Read More

Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providing treatment for type 2 diabetes. Canada is the first G7 nation to approve this medication. The launch follows a recent introduction in India. Dr Reddy's aims to expand access to these therapies globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WrVdyDF
via IFTTT

Read More